TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating
TD Cowen Remains a Buy on Kezar Life Sciences (KZR)
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Maintains Target Price $2
Maintaining Hold on Kezar Life Sciences Amid Safety Concerns and Financial Valuation
JonesTrading Maintains Kezar Life Sciences(KZR.US) With Hold Rating
Wells Fargo Maintains Kezar Life Sciences(KZR.US) With Hold Rating, Maintains Target Price $2
TD Cowen Maintains Kezar Life Sciences(KZR.US) With Buy Rating
Kezar Life Sciences Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Achieve Life Sciences (ACHV) and Kezar Life Sciences (KZR)
Buy Rating on Kezar Life Sciences Backed by Promising Zetomipzomib Clinical Trials
Kezar Life Sciences Price Target Cut to $7.00/Share From $20.00 by HC Wainwright & Co.
Kezar Life Sciences Analyst Ratings
Kezar Life Sciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Hold Rating on Kezar Life Sciences Amid Trial Progress and Efficacy Concerns
Analysts' Opinions Are Mixed on These Healthcare Stocks: Kezar Life Sciences (KZR), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Cue Health (HLTH)
Kezar Life Sciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Kezar Life Sciences, Maintains $20 Price Target
Kezar Life Sciences Analyst Ratings
Analysts' Top Healthcare Picks: DocGo (DCGO), Kezar Life Sciences (KZR)